2026-05-22T00:02:10Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/172522024-11-30T01:19:45Zcom_20.500.12105_2173com_20.500.12105_2051col_20.500.12105_19597
Repisalud
author
Kanellis, Dimitris C
author
Zisi, Asimina
author
Skrott, Zdenek
author
Lemmens, Bennie
author
Espinoza, Jaime A
author
Kosar, Martin
author
Björkman, Andrea
author
Li, Xuexin
author
Arampatzis, Stefanos
author
Bartkova, Jirina
author
Andújar-Sánchez, Miguel
author
Fernandez-Capetillo, Oscar
author
Mistrik, Martin
author
Lindström, Mikael S
author
Bartek, Jiri
2024-01-22T13:01:47Z
2024-01-22T13:01:47Z
2023-07
Cell Death Differ. 2023 ;30(7):1666-1678.
10.1038/s41418-023-01167-4
1476-5403
Cell death and differentiation
37142656
http://hdl.handle.net/20.500.12105/17252
Drug repurposing is a versatile strategy to improve current therapies. Disulfiram has long been used in the treatment of alcohol dependency and multiple clinical trials to evaluate its clinical value in oncology are ongoing. We have recently reported that the disulfiram metabolite diethyldithiocarbamate, when combined with copper (CuET), targets the NPL4 adapter of the p97VCP segregase to suppress the growth of a spectrum of cancer cell lines and xenograft models in vivo. CuET induces proteotoxic stress and genotoxic effects, however important issues concerning the full range of the CuET-evoked tumor cell phenotypes, their temporal order, and mechanistic basis have remained largely unexplored. Here, we have addressed these outstanding questions and show that in diverse human cancer cell models, CuET causes a very early translational arrest through the integrated stress response (ISR), later followed by features of nucleolar stress. Furthermore, we report that CuET entraps p53 in NPL4-rich aggregates leading to elevated p53 protein and its functional inhibition, consistent with the possibility of CuET-triggered cell death being p53-independent. Our transcriptomics profiling revealed activation of pro-survival adaptive pathways of ribosomal biogenesis (RiBi) and autophagy upon prolonged exposure to CuET, indicating potential feedback responses to CuET treatment. The latter concept was validated here by simultaneous pharmacological inhibition of RiBi and/or autophagy that further enhanced CuET's tumor cytotoxicity, using both cell culture and zebrafish in vivo preclinical models. Overall, these findings expand the mechanistic repertoire of CuET's anti-cancer activity, inform about the temporal order of responses and identify an unorthodox new mechanism of targeting p53. Our results are discussed in light of cancer-associated endogenous stresses as exploitable tumor vulnerabilities and may inspire future clinical applications of CuET in oncology, including combinatorial treatments and focus on potential advantages of using certain validated drug metabolites, rather than old, approved drugs with their, often complex, metabolic profiles.
eng
Actionable cancer vulnerability due to translational arrest, p53 aggregation and ribosome biogenesis stress evoked by the disulfiram metabolite CuET.
journal article
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
URL
https://repisalud.isciii.es/bitstreams/7aad7fc0-a631-484f-bb2f-bf38d9af101f/download
File
MD5
9163434e735deaeb1d0d81d8a5f962e6
6955310
application/pdf
actionablecancervulnerability_2023.pdf
URL
https://repisalud.isciii.es/bitstreams/ad2f0742-a901-4b39-97e3-dbfe70b792f5/download
File
MD5
a797362f5a11b43329c5bae76690e5ed
1781798
application/pdf
actionablecancervulnerability_reporting summary_2023.pdf
URL
https://repisalud.isciii.es/bitstreams/723406da-9165-42f7-95de-4080e7e3afb2/download
File
MD5
1ccba7f403b43d22f6ee11629d09d382
20888
application/vnd.openxmlformats-officedocument.wordprocessingml.document
41418_2023_1167_MOESM2_ESM.docx
URL
https://repisalud.isciii.es/bitstreams/91c763d4-2744-4cb6-9411-a262bc12ef41/download
File
MD5
ea639dda913db8f97e157f15fd144bdf
929305
application/pdf
actionablecancervulnerability_supl figure_2023.pdf
URL
https://repisalud.isciii.es/bitstreams/1b3c4faa-ad48-4e74-b516-cc5111a3818c/download
File
MD5
03b43e3b16fb329bc9ec2a6d389f62a6
213629
application/pdf
actionablecancervulnerability_supl images_2023.pdf
URL
https://repisalud.isciii.es/bitstreams/94141b88-b21d-4497-a100-c9d43a8f0470/download
File
MD5
b19e9b0b5184f6e497c32f5be8841401
1072811
application/vnd.openxmlformats-officedocument.spreadsheetml.sheet
41418_2023_1167_MOESM5_ESM.xlsx
URL
https://repisalud.isciii.es/bitstreams/41e39988-9198-4597-8495-e041e5e77f12/download
File
MD5
75609a8171d968599b8899da0ce20012
70296
text/plain
actionablecancervulnerability_2023.pdf.txt
URL
https://repisalud.isciii.es/bitstreams/d1795b76-338d-4c1d-893d-68021804a232/download
File
MD5
30e1a35febdf5d3fc5010c59d194a969
5679
text/plain
actionablecancervulnerability_reporting summary_2023.pdf.txt
URL
https://repisalud.isciii.es/bitstreams/0d9ceed5-69e3-4f06-8c29-6f69a84350d4/download
File
MD5
70b7c1fba35b7d088442f455bf8ac386
4392
text/plain
actionablecancervulnerability_supl figure_2023.pdf.txt
URL
https://repisalud.isciii.es/bitstreams/1c884e1e-aa97-4f47-a38f-6d53e213ba1f/download
File
MD5
d1ee8e6e5806870e52ce2e4cd1f2e88d
639
text/plain
actionablecancervulnerability_supl images_2023.pdf.txt
URL
https://repisalud.isciii.es/bitstreams/04f4adf5-2b86-43f4-9f41-d73ced34536b/download
File
MD5
9bb620c0e9d9761856414855dc181222
6461
text/plain
41418_2023_1167_MOESM2_ESM.docx.txt
URL
https://repisalud.isciii.es/bitstreams/e9841f4d-ca4d-44bb-a77a-f0d9ff0464cf/download
File
MD5
464b04f9f7303093c57b427d92cf3324
100000
text/plain
41418_2023_1167_MOESM5_ESM.xlsx.txt